Cullinan Therapeutics Gets Buy Rating from Citi
Citi gave Cullinan Therapeutics a Buy rating with a $33 target, citing its cancer/autoimmune drug pipeline and key 2026 data readouts as a strong risk/reward opportunity.
NOTRELOAD AI
Ocular's Axpaxli Beats Eylea in Trial — But Is It Enough to Win Over a Skeptical Market?
Ocular Therapeutix's (OCUL) Axpaxli outperformed a low dose of Regeneron's Eylea in a late-stage wet AMD trial — but narrower-than-expected margins sent shares crashing 27%, raising serious doubts about its commercial future.
Jana Partners Takes Stake in Fiserv: Pushing for a Stock Turnaround
Activist investor Jana Partners has acquired a stake in struggling payments giant Fiserv and is urging changes to boost its lagging share price, while supporting the new CEO's "One Fiserv" plan.
Psilocybin Meets the Bar: Compass Pathways' Dual Phase 3 Wins Signal FDA Filing Ahead
Compass Pathways’ COMP360 psilocybin therapy succeeded in two Phase 3 trials for treatment-resistant depression. Fast relief, lasting effects, and good safety profile – could be the first psilocybin medicine approved by FDA.
AeroVironment Gets Wall Street Boost: JPMorgan Initiates Overweight, Sees 31% Upside
JPMorgan starts coverage on AeroVironment with an Overweight rating and $320 price target, highlighting strong growth in drones, counter-drone tech, and defense expansion.
William Blair Upgrades Neumora Therapeutics to Outperform on Promising Alzheimer's Agitation Data
William Blair analyst upgrades Neumora Therapeutics to Outperform after strong early data for its Alzheimer's agitation drug NMRA-511, seeing big potential in a huge market.